Treatment outcomes in multidrug-resistant tuberculosis according to pyrazinamide susceptibility
S Park, KW Jo, TS Shim - The International Journal of …, 2020 - ingentaconnect.com
BACKGROUND: Pyrazinamide (PZA) is an important anti-tuberculosis drug for multidrug-
resistant tuberculosis (MDR-TB). However, PZA has recently been demoted within the …
resistant tuberculosis (MDR-TB). However, PZA has recently been demoted within the …
Impact of pyrazinamide resistance on multidrug-resistant tuberculosis in Karakalpakstan, Uzbekistan
J Kuhlin, C Smith, A Khaemraev, Z Tigay… - … of tuberculosis and …, 2018 - ingentaconnect.com
SETTING: The World Health Organization (WHO) recommends the inclusion of
pyrazinamide (PZA) in treatment regimens for multidrug-resistant tuberculosis (MDR-TB) …
pyrazinamide (PZA) in treatment regimens for multidrug-resistant tuberculosis (MDR-TB) …
Pyrazinamide may improve fluoroquinolone-based treatment of multidrug-resistant tuberculosis
KC Chang, CC Leung, WW Yew… - Antimicrobial agents …, 2012 - Am Soc Microbiol
The role of pyrazinamide in the current treatment of multidrug-resistant (MDR) tuberculosis
(TB) is uncertain. From a territory-wide registry of MDR-TB cases diagnosed between 1995 …
(TB) is uncertain. From a territory-wide registry of MDR-TB cases diagnosed between 1995 …
Introducing molecular testing of pyrazinamide susceptibility improves multidrug-resistant tuberculosis treatment outcomes: a prospective cohort study
F Sun, Y Li, Y Chen, W Guan, X Jiang… - European …, 2019 - Eur Respiratory Soc
The current treatment for multidrug-resistant tuberculosis (MDR-TB) takes a lengthy period of
18–24 months and has a poor cure rate of 50–60%. A multicenter, prospective cohort study …
18–24 months and has a poor cure rate of 50–60%. A multicenter, prospective cohort study …
Drug Exposure and Susceptibility of Pyrazinamide Correlate with Treatment Response in Pyrazinamide-Susceptible Patients with Multidrug-Resistant Tuberculosis
S Dong, G Shao, L Davies Forsman, S Wang, S Wang… - Pharmaceutics, 2024 - mdpi.com
Exploring the influence of pyrazinamide exposure and susceptibility on treatment response
is crucial for optimizing the management of multidrug-resistant tuberculosis (MDR-TB). This …
is crucial for optimizing the management of multidrug-resistant tuberculosis (MDR-TB). This …
Introducing molecular testing of pyrazinamide susceptibility improves MDR-TB treatment outcomes: a prospective cohort study
F Sun, Y Li, Y Chen, W Guan, X Jiang… - European …, 2018 - Eur Respiratory Soc
The current treatment for multidrug-resistant tuberculosis (MDR-TB) takes a lengthy period of
18–24 months and has a poor cure rate of 50–60%. A multi-center, prospective cohort study …
18–24 months and has a poor cure rate of 50–60%. A multi-center, prospective cohort study …
[HTML][HTML] The influence of pyrazinamide monoresistance on treatment outcomes in tuberculosis patients from Southern China
S Tan, Y Rao, J Guo, Y Tan, X Cai, H Kuang… - Journal of Tuberculosis …, 2016 - scirp.org
This study aimed to explore the influence of pyrazinamide (PZA) monoresistance on the
treatment outcome of otherwise drug susceptible tuberculosis (TB). A cohort of 194 TB …
treatment outcome of otherwise drug susceptible tuberculosis (TB). A cohort of 194 TB …
'ZS-MDR-TB' versus 'ZR-MDR-TB': improving treatment of MDR-TB by identifying pyrazinamide susceptibility
Y Zhang, K Chiu Chang, CC Leung… - Emerging microbes & …, 2012 - Taylor & Francis
Indispensable for shortening treatment of drug-susceptible tuberculosis (TB), pyrazinamide
(PZA, Z) is also essential in the treatment of multidrug-resistant (MDR)-TB. While resistance …
(PZA, Z) is also essential in the treatment of multidrug-resistant (MDR)-TB. While resistance …
Pyrazinamide is a two-edged sword: do WHO guidelines matter?
KC Chang, WW Yew, Y Zhang - Antimicrobial agents and …, 2018 - Am Soc Microbiol
Two recent studies have suggested that pyrazinamide is a two-edged sword in the treatment
of multidrug-resistant tuberculosis (MDR-TB). Kempker et al. showed good penetration of …
of multidrug-resistant tuberculosis (MDR-TB). Kempker et al. showed good penetration of …
Prevalence and molecular characterization of pyrazinamide resistance among multidrug-resistant Mycobacterium tuberculosis isolates from Southern China
Y Pang, D Zhu, H Zheng, J Shen, Y Hu, J Liu… - BMC Infectious …, 2017 - Springer
Background Pyrazinamide (PZA) plays a unique role in the treatment for multidrug-resistant
tuberculosis (MDR-TB) in both first-and second-line regimens. The aim of this study was to …
tuberculosis (MDR-TB) in both first-and second-line regimens. The aim of this study was to …